Caraco vs. Novo Nordisk
Issue: Whether a generic drug manufacturer may sue the company that produces the brand-name version of the drug to require it to correct information filed with the Food and Drug Administration, information that is relevant to the agency's decision whether to approve the generic version of the drug.
Caraco is a pharmaceutical laboratory who's main job is to create affordable medication for patients
Novo Nordisk is a healthcare company and worldwide leader in diabetes care and medication
The case which revolves around Caraco diabetes drug repaglinide, Caraco certified that its' drug label wouldn't conflict with respondent novo nordisk repaglinide-metformin use combination
Caraco is a pharmaceutical laboratory who's main job is to create affordable medication for patients
Novo Nordisk is a healthcare company and worldwide leader in diabetes care and medication
The case which revolves around Caraco diabetes drug repaglinide, Caraco certified that its' drug label wouldn't conflict with respondent novo nordisk repaglinide-metformin use combination
The case is whether a patented drug that is filed by the FDA can be sued by the generic maker of that similar drug for not given correct information regarding the exact drug and everything included in it. (chemical mixtures etc.)
Comments
No comments have been posted yet.
Log in to post a comment.